GSK's ADC Pipeline Shows Promise with Latest Data from Hansoh Partnership

GSK's antibody-drug conjugate (ADC) pipeline is gaining momentum, with encouraging data presented at the European Society for Medical Oncology (ESMO) congress in Berlin. The pharmaceutical giant's collaboration with Chinese company Hansoh is yielding positive results, particularly in the realm of oncology.

B7-H4-Targeted ADC Shows Promising Results in Ovarian Cancer

GSK5733584 (HS-20089), a B7-H4-targeted ADC, demonstrated significant efficacy in a phase 2 study of patients with platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The study, conducted by Hansoh, reported a confirmed overall response rate (ORR) of 48.5% and a disease control rate of 75.8% across 33 enrolled patients.

B7-H3-Targeted ADC Exhibits Potential in Sarcoma Treatment

Another ADC in GSK's portfolio, GSK5764227 (HS-20093), targeting B7-H3, showed promising results in osteosarcoma and other sarcoma types. In a cohort of 44 evaluable adults and adolescents with osteosarcoma, the ORR reached 17.2% at the 12 mg/kg dose, with a progression-free survival (PFS) of 8.4 months. Notably, in a subgroup of patients with soft-tissue sarcoma, the ORR was 23.1% with a PFS of 9.4 months.

GSK's Oncology Pipeline Expansion

Hesham Abdullah, M.D., global head of oncology, research & development at GSK, emphasized the company's focus on its own studies of both ADCs. GSK has planned five phase 3 studies for the B7-H4-targeted ADC (GSK5733584) in endometrial and ovarian cancer, set to launch in the first half of 2026. Additionally, the first patient has been dosed in a phase 3 study of GSK5764227 in small cell lung cancer.

The company's oncology portfolio has seen significant growth over the past 18 to 24 months, including successful phase 3 trials for Blenrep in multiple myeloma and Jemperli in endometrial cancer. GSK has also bolstered its pipeline through strategic acquisitions, such as the purchase of precision medicine biotech IDRx.

As the pharmaceutical industry continues to evolve, GSK's focus on ADCs and targeted therapies positions the company as a key player in the oncology space. With a robust clinical-stage pipeline and ongoing research efforts, GSK is poised to make significant contributions to cancer treatment in the coming years.